The Potential Clinical Impact of Implementing Different COVID-19 Boosters in Fall 2022 in the United States

Michele A. Kohli, Michael Maschio, Amy Lee, Kelly Fust, Nicolas Van de Velde, Philip O. Buck, Milton C. Weinstein
doi: https://doi.org/10.1101/2022.07.19.22277824

Article Information

doi 
https://doi.org/10.1101/2022.07.19.22277824
History 
  • July 22, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Michele A. Kohli, PhD1,*,
  2. Michael Maschio, MSc1,
  3. Amy Lee, PhD1,
  4. Kelly Fust, MSc1,
  5. Nicolas Van de Velde, PhD2,
  6. Philip O. Buck, PhD2 and
  7. Milton C. Weinstein, PhD3
  1. 1Quadrant Health Economics Inc; 92 Cottonwood Crescent, Cambridge, Ontario, Canada
  2. 2Moderna Inc; 200 Technology Square, Cambridge, MA, United States
  3. 3Harvard T.H. Chan School of Public Health, 718 Huntington Avenue, Boston, Massachusetts, USA
  1. ↵*Correspondence:
    Michele Kohli, Quadrant Health Economics Inc.; 92 Cottonwood Crescent, Cambridge, Ontario, Canada; michele.kohli{at}quadrantHE.com
Back to top
Posted July 22, 2022.
Download PDF

Supplementary Material

Data/Code
Email
The Potential Clinical Impact of Implementing Different COVID-19 Boosters in Fall 2022 in the United States
Michele A. Kohli, Michael Maschio, Amy Lee, Kelly Fust, Nicolas Van de Velde, Philip O. Buck, Milton C. Weinstein
medRxiv 2022.07.19.22277824; doi: https://doi.org/10.1101/2022.07.19.22277824
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area